Last updated: February 15, 2026
What Are the Patentability Criteria for Biopharmaceuticals in Malta?
Malta’s patent law aligns with European Union standards, adhering to the European Patent Convention (EPC) and the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). To qualify for patent protection, biopharmaceutical inventions must meet the following:
-
Novelty: The invention must not be publicly disclosed before filing. Public disclosures include scientific publications, presentations, or prior patent applications.
-
Inventive Step: The invention cannot be obvious to someone skilled in the field. Commonly, inventions involving new formulations, methods, or uses of known molecules qualify if they demonstrate a non-obvious technical advancement.
-
Industrial Applicability: The invention must be capable of being used in some kind of industry, including medical or pharmaceutical manufacturing.
-
Excluded Subject Matter: Discoveries, mere discoveries of natural substances, and methods of treatment or diagnosis are generally excluded from patentability. Under EPC Article 53(c), methods of treatment of humans or animals are not patentable, aligning with international standards.
How Enforceability Is Maintained for Biopharmaceutical Patents in Malta
Malta’s patent enforcement relies on national courts, supported by EU patent regulations. Key factors include:
-
Patent Registration: As a member of the European Patent Organisation, Malta recognizes European patents validated locally or directly filed national patents.
-
Validity Challenges: Patents can be challenged for invalidity based on non-compliance with patentability criteria, procedural irregularities, or disclosure issues. Validity is often scrutinized through court proceedings.
-
Infringement Actions: Patent holders can initiate civil proceedings for infringement. Courts can award injunctions, damages, and account for profits. Enforcement also benefits from Malta’s adherence to EU directives on intellectual property rights enforcement.
-
Data Exclusivity: Data exclusivity for biologics or pharmaceuticals may extend beyond patent life, which provides a supplementary layer of exclusivity, especially relevant for biologics.
What Is the Scope of Claims for Biopharmaceutical Patents?
Claims define the breadth of patent protection. For biopharmaceuticals, claims typically fall into:
-
Product Claims: Cover specific molecules, such as a novel protein, antibody, or gene therapy vector.
-
Process Claims: Cover methods of manufacturing, purification, or formulation. Claims must be sufficiently specific to distinguish from existing methods.
-
Use Claims: Cover new therapeutic applications of known substances, such as a new indication for a known biologic.
-
Formulation Claims: Cover specific pharmaceutical compositions, including excipients and delivery systems.
-
Genetic or Biologic Claims: Cover sequences of DNA/RNA or biologically derived molecules with specific functional attributes.
Claims must be drafted carefully to avoid overly broad or ambiguous language, which can lead to invalidity or difficulties during enforcement. Precision in claim scope enhances enforceability and reduces patent clearance risks.
Comparison with European Patent Law
Malta’s patent regime for biopharmaceuticals mirrors European standards, with notable distinctions:
| Aspect |
Malta Patent Office |
European Patent Convention (EPC) |
| Patent Scope |
Similar to EPC, considers European patents validated in Malta |
Standard for European patents |
| Patent Term |
20 years from filing |
20 years from filing |
| Data Exclusivity |
Typically 8-11 years for biologics in UE, Malta aligns with EU policies |
8+ years for biologics under EU regulations |
| Utility Requirement |
Must be capable of industrial use |
Same as EPC |
| Patentability of Methods of Treatment |
Not patentable |
Not patentable |
Key Challenges and Opportunities
-
Challenges: Caution in drafting claims to avoid encompassing unpatentable subject matter, such as natural phenomena or methods of medical treatment. Patent oppositions can challenge validity, especially if prior art is overlooked.
-
Opportunities: Malta’s strategic position within the EU enables patent validation across member states, expanding protection scope. The jurisdiction is a favorable environment for startups due to streamlined procedures and EU-aligned standards.
Final Notes
Patent rights for biopharmaceuticals in Malta are governed by a framework that aligns with EU laws. The permit involves navigating strict criteria for patentability, establishing enforceability through national and European courts, and crafting claims that balance broad protection with legal clarity. Robust patent drafting—focused on novelty, inventive step, and precise claim scope—is crucial for enforcement.
Key Takeaways
- Maltese patent law follows EPC standards, emphasizing novelty, inventive step, and industrial applicability.
- Methods of medical treatment are excluded from patentability, consistent with EU practice.
- Enforcement is through Maltese courts, with invalidity and infringement actions being common tools.
- The scope of claims should be precise, covering products, processes, uses, and formulations according to strategic needs.
- Malta offers a gateway to the EU patent system, expanding overall patent protection for biopharmaceutical innovations.
FAQs
1. Can biopharmaceutical methods of treatment be patented in Malta?
No. Methods of treatment for humans or animals are excluded from patentability under Malta law, consistent with EPC and EU standards.
2. How long does patent protection last for biopharmaceuticals in Malta?
The standard patent term is 20 years from the initial filing date, subject to maintenance fees.
3. Are biologics eligible for patent protection in Malta?
Yes. Biologics, including proteins, antibodies, or gene therapies, are patentable if they meet all criteria.
4. What are common pitfalls in patent claims for biopharmaceuticals?
Overly broad claims, vague language, or claims that encompass natural substances can cause invalidity or enforcement issues.
5. How does Malta’s patent system support biotech startups?
Its alignment with EU standards allows startups to secure regional patent protection efficiently, with an accessible legal and procedural environment.
References
[1] European Patent Convention (EPC).
[2] Malta Patent Law.
[3] EU Regulations on Data Exclusivity for Biologics.
[4] World Intellectual Property Organization (WIPO). Malta Patent Office Overview.
[5] European Patent Office (EPO) Guidelines for Examination.
